Background/Aims Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients.
Methods We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan’s cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray’s cumulative incidence and Cox subdistribution hazards models to analyze HCC development.
Result s: Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not using metformin had a 51% increased risk of HCC compared to non-DM patients, while HLP patients on statins had a 50% reduced risk compared to those without HLP. The 5-year HCC incidence was significantly higher for metformin non-users (16.5%) versus non-DM patients (11.3%; adjusted sub-distribution hazard ratio [aSHR]=1.51; P=0.007) and metformin users (3.1%; aSHR=1.59; P=0.022). Statin use in HLP patients correlated with a lower HCC risk (3.8%) compared to non-HLP patients (12.5%; aSHR=0.50; P<0.001). Notably, the increased HCC risk associated with non-use of metformin was primarily seen in non-cirrhotic patients, whereas statins decreased HCC risk in both cirrhotic and non-cirrhotic patients.
Conclusions Metformin and statins may have a chemopreventive effect against HCC in CHC patients who failed antiviral therapy. These results support the need for personalized preventive strategies in managing HCC risk.
Exploiting tumor lineage features for precision cancer therapy Lois M. Kelly, Nina Fenouille, Kris C. Wood, Alexandre Puissant Trends in Cancer.2026;[Epub] CrossRef
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic Hiroyuki Suzuki, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert, Raymond T. Chung, Takumi Kawaguchi, Yujin Hoshida Hepatology.2025;[Epub] CrossRef
Reply to the comment on “High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C” Yen-Chun Chen, Ming-Lung Yu Journal of the Formosan Medical Association.2025;[Epub] CrossRef
Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma Natchaya Polpichai, Sakditad Saowapa, Pojsakorn Danpanichkul, Shu-Yen Chan, Leandro Sierra, Johanna Blagoie, Chitchai Rattananukrom, Pimsiri Sripongpun, Apichat Kaewdech Journal of Clinical Medicine.2024; 13(22): 6770. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management Karina Gonzalez-Aldaco, Luis A. Torres-Reyes, Claudia Ojeda-Granados, Leonardo Leal-Mercado, Sonia Roman, Arturo Panduro Clinics and Practice.2024; 14(6): 2542. CrossRef
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC) Davide Misceo, Gabriele Mocciaro, Simona D’Amore, Michele Vacca Nutrition & Metabolism.2024;[Epub] CrossRef
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Clin Mol Hepatol 2024;30(3):375-387. Published online March 26, 2024
Background/Aims Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAgpositive or -negative chronic HBV infection.
Methods Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twenty-five patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days.
Result s: A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths.
Conclusions In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.
Citations
Citations to this article as recorded by
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fu-Sheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon-Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei-Jer Chen, Hong You, Ming Hepatology International.2025; 19(4): 773. CrossRef
Mise à jour concernant le traitement des hépatites virales Marie Ongaro, Francesco Negro Schweizer Gastroenterologie.2025; 6(2): 46. CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients” Hae Lim Lee, Jeong Won Jang Clinical and Molecular Hepatology.2024; 30(4): 692. CrossRef
Background/Aims Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy.
Methods We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment.
Result s: The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset.
Conclusions Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.
Citations
Citations to this article as recorded by
AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim Journal of Hepatology.2025; 82(3): 456. CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Explainable machine learning for the assessment of donor grafts in liver transplantation Liang Zhixing, Ye Linsen, Jiang Peng, Dong Siyi, Yu Haoyuan, Li Kun, Li Siqi, Hu Yongwei, Zhang Mingshen, Liu Wei, Li Hua, Yi Shuhong, Chen Guihua, Xu Xiao, Zheng Shusen, Yang Yang Hepatology Research.2025; 55(6): 908. CrossRef
Role of risk factors and their variable types in predicting noise-induced hearing loss using artificial intelligence algorithms Zhengheng Zhang, Longteng Jiang, Meibian Zhang, Yuan Pan, Jinnan Zheng, Anqi Liu, Weijiang Hu, Xin Jin Hearing Research.2025; 465: 109353. CrossRef
Artificial Intelligence and Machine Learning Applications in Liver Disease Bhargav Vemulapalli, Meghana Ghattu, Kavya Atluri, James Lee, Vinod Rustgi Clinics in Liver Disease.2025; 29(4): 755. CrossRef
Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response Aya I. Abdelaziz, Eman Abdelsameea, Sara A. Wahdan, Doaa Elsherbiny, Zeinab Zakaria, Samar S. Azab Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination Daniela Toma, Lucreția Anghel, Diana Patraș, Anamaria Ciubară Viruses.2025; 17(8): 1069. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Identifying new strategies to combat cytomegalovirus by integrating existing and innovative approaches in diagnosis and treatment Nargiz Imamova, Ayten Feteliyeva, Adil M. Allahverdiyev Future Virology.2025; 20(10): 379. CrossRef
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions Kirolos Eskandar iLIVER.2025; 4(4): 100205. CrossRef
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan Chin-Wei Chang, Wei-Fan Hsu, Kuo-Chih Tseng, Chi-Yi Chen, Pin-Nan Cheng, Chao-Hung Hung, Ching-Chu Lo, Ming-Jong Bair, Chien-Hung Chen, Pei-Lun Lee, Chun-Yen Lin, Hsing-Tao Kuo, Chun-Ting Chen, Chi-Chieh Yang, Jee-Fu Huang, Chi-Ming Tai, Jui-Ting Hu, Chih Digestive Diseases and Sciences.2024; 69(9): 3501. CrossRef
Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries Guilherme Silva Julian, Wen-Yi Shau, Hsu-Wen Chou, Sajita Setia JMIR Medical Informatics.2024; 12: e58548. CrossRef
The role of artificial intelligence in the management of liver diseases Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study Khalid M. Al-Naamani, Heba Omar, Said A. Al Busafi, Halima H. Al Shuaili, Zakariya Al-Naamani, Murtadha Al-Khabori, Elias A. Said, Abdullah H. AlKalbani, B. R. Kamath, Bashar Emad, Shahina Daar, Lolo Alhajri, Alya AlKalbani, Zainab AlFarsi, Haifa Alzuhaib Journal of Clinical Medicine.2024; 13(23): 7411. CrossRef
Background/Aims Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited.
Methods We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. Thesafety profiles were reported.
Result s: The SVR12 rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5–94.2%), 94.1% (95% CI, 87.8–97.3%), and 100% (95% CI, 96.2–100%). Number of patients who failed to achieve SVR12 were attributed to virologic failures. The SVR12 rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR12, 84.4% and 64.6% had improved Child-Pugh and model for endstage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score ≥15 was associated with an improved MELD score of ≥3 (odds ratio, 4.13; 95% CI, 1.16–14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m2/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m2/month; P<0.001).
Conclusions SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.
Citations
Citations to this article as recorded by
2025 KASL clinical practice guidelines for management of hepatitis C Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
Role of etiological therapy in achieving recompensation of decompensated liver cirrhosis Dmitry V Garbuzenko World Journal of Hepatology.2025;[Epub] CrossRef
Effectiveness of etiotropic therapy in achieving recompensation of cirrhosis D.V. Garbuzenco Russian Journal of Evidence-Based Gastroenterology.2025; 14(2): 68. CrossRef
Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study Jae Hyun Yoon, Chang Hun Lee, Hoon Gil Jo, Ju-Yeon Cho, Jin Dong Kim, Jin Won Kim, Ga Ram You, Sung Bum Cho, Sung Kyu Choi Viruses.2025; 17(7): 949. CrossRef
Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis Jing Xiao, Xinnian Zhang, Xiaozhou Mao, Shunhao Lai, Shuangli Li, Yunjian Sheng Journal of Viral Hepatitis.2025;[Epub] CrossRef
Oral carbohydrate intake before selective laparoscopic liver resection reduces insulin resistance and enhances recovery Hongqiong Li American Journal of Translational Research.2025; 17(8): 6080. CrossRef
Recent Advances in the Treatment of Chronic Hepatitis C Suk Bae Kim The Korean Journal of Gastroenterology.2025; 85(4): 475. CrossRef
Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study Mengyue Li, Yiting Li, Ying Zhang, Xiangyang Wang, Chaoshuang Lin Medicine.2024; 103(7): e37212. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients Jiayi Wang, Lingyao Du, Dongmei Zhang, Chen Zhou, Yilan Zeng, Miao Liu, Xing Cheng, Xiaona Song, Han Chen, Ning Han, Enqiang Chen, Hong Tang Journal of Virus Eradication.2024; 10(4): 100571. CrossRef
Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response Chen‐Hua Liu, Chun‐Jen Liu, Tung‐Hung Su, Tai‐Chung Tseng, Pei‐Jer Chen, Jia‐Horng Kao Advances in Digestive Medicine.2023; 10(1): 34. CrossRef
Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir Pei‐Kai Su, Te‐Sheng Chang, Shui‐Yi Tung, Kuo‐Liang Wei, Chien‐Heng Shen, Yung‐Yu Hsieh, Wei‐Ming Chen, Yi‐Hsing Chen, Chun‐Hsien Chen, Chih‐Wei Yen, Huang‐Wei Xu, Wei‐Ling Tung, Kao‐Chi Chang Advances in Digestive Medicine.2023; 10(3): 150. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur Scientific Reports.2023;[Epub] CrossRef
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung W The Korean Journal of Internal Medicine.2023; 38(4): 504. CrossRef
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Sam Viruses.2023; 15(10): 2026. CrossRef
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus–related cirrhosis Chen-Hua Liu, Chun-Jen Liu, Jia-Horng Kao Journal of the Chinese Medical Association.2022; 85(5): 647. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler Biomedicines.2022; 10(12): 3152. CrossRef
First
Prev
